1. Please check and comment entries here.
Table of Contents

    Topic review

    Gut Reaction to SIV&SHIV Infection

    Subjects: Virology | Immunology
    View times: 5
    Submitted by: Megan O'Connor


    SIV and SHIV-infected NHPs exhibit a range of viral burdens, pathologies, and responses to combinatorial antiretroviral therapy (cART) regimens and the choice of the NHP model for AIDS could influence outcomes in studies investigating interventions. Previously, in rhesus macaques (RMs) we showed that maintenance of mucosal Th17/Treg homeostasis during SIV infection correlated with a better virological response to cART. Here, in RMs we compared viral kinetics and dysregulation of gut homeostasis, defined by T cell subset disruption, during highly pathogenic SIVΔB670 compared to SHIV-1157ipd3N4 infection.SHIV infection resulted in lower acute viremia and less disruption to gut CD4 T-cell homeostasis. Additionally, 24/24 SHIV-infected versus 10/19 SIV-infected animals had sustained viral suppression <100 copies/mL of plasma after 5 months of cART. Significantly, the more profound viral suppression during cART in a subset of SIV and all SHIV-infected RMs corresponded with less gut immune dysregulation during acute SIV/SHIV infection, defined by maintenance of the Th17/Treg ratio. These results highlight significant differences in viral control during cART and gut dysregulation in NHP AIDS models and suggest that selection of a model may impact the evaluation of candidate therapeutic interventions for HIV treatment and cure strategies. 

    1. Introduction

    Since the discovery of HIV in the 1980s, non-human primate (NHP) models of AIDS have been critical for understanding HIV disease pathogenesis and evaluating interventions for HIV prevention and treatment [1]. Infection of NHPs with simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) hybrids have been widely used as models of HIV infection. Vaccines directed towards HIV envelope immunogens cannot be tested using an SIV challenge [2]; therefore, SHIVs were developed by replacing SIV with HIV-1 genes to create a better HIV vaccine challenge model. SIV and SHIV infection recapitulate many aspects of HIV disease, including peripheral CD4 depletion, progression to AIDS, and disruption of gut homeostasis, including depletion of CD4 and T helper 17 (Th17) cells and increased mucosal immune activation [3][4][5]. However, there are significant differences in SIV and SHIV pathogenesis with SIV generally resulting in more accelerated and severe disease [6]. It remains unknown whether SHIV or SIV infection better recapitulates the gut dysfunction during HIV infection and its impact on combinatorial antiretroviral therapy (cART) or immune-based therapeutic interventions.
    Reduction in HIV replication by cART has drastically improved the lives of people living with HIV. However, even with cART adherence and viral suppression, HIV reservoirs persist in lymphoid and mucosal tissues [7]. The gastrointestinal tract is a concentrated site of CD4+ T cells, a principal site of early HIV replication and a persistent reservoir during cART in virally suppressed, HIV-infected individuals. Additionally, significant barriers to the success of therapeutic interventions in the gut include mucosal dysregulation and persistent immune activation. Therefore, strategies aiming to augment the decline in mucosal integrity and function may be necessary to achieve a functional cure [8]. We previously showed that rhesus macaques (RMs) infected with SIVΔB670 exhibited highly variable responses to cART [9]. Furthermore, the ability to respond to therapeutic vaccination and control viral rebound after stopping cART correlated with the virological response to cART prior to vaccination [9][10]. We also observed significant loss in mucosal integrity including declines in the Th17/T regulatory (Treg) CD4 T-cell ratio in the colon during acute infection and cART therapy in SIV-infected RMs that correlated with higher immune activation, greater microbial translocation, and increased peripheral immune exhaustion [11]. During HIV infection in humans, gut dysregulation, including impairment of gut Th17 cell responses, is also associated with systemic immune activation and more rapid HIV disease progression [4][12][13].

    To determine whether impaired mucosal responses also occurred in a SHIV model, we sought to compare viral replication, cART viral suppression, and gut T cell immune dysregulation during SHIV-1157ipd3N4 infection with SIVΔB670 infection in RM, as previously reported [11]. SIVΔB670 is highly pathogenic and was passaged in vitro to be less pathogenic, but animals still progress to AIDS in less than a year [14][15]. SHIV-1157ipd3N4 is a CCR5-tropic SHIV containing an HIV clade C envelope and was adapted for use in NHPs by passage in vivo and causes progression to AIDS in 2–5 years [16][17]. We demonstrate that both strains support high levels of viral replication in rhesus macaques, with SHIV-1157ipd3N4-infected animals showing lower acute viral burdens and greater virologic control, defined as sustained suppression of viral load below 100 viral RNA copies/mL, during cART. Analysis of mucosal CD4 T-cells during acute infection and following >5 months of cART revealed lower immune dysregulation, defined by an imbalance of Th17 and Treg cells, and lower levels of T-cell activation during cART in SHIV-1157ipd3N4-infected animals indicating overall slower SHIV-related gut disease progression. These results indicate that selection of a pre-clinical NHP model can influence outcomes in the evaluation of HIV treatment and prevention strategies.

    2. Lower Acute Gut Immune Dysfunction in SIV/SHIV-Infected Macaques Is Associated with Greater Viral Control by cART

    We next sought to understand the role of SIV/SHIV gut pathogenesis, in particular CD4 cell subset dysregulation, on viral control during cART. To test this, we compared the fold change in colonic CD4 T-cell populations during acute SIV/SHIV infection to the levels of viral burden following cART. This analysis revealed that maintenance or increases in Th17, Th17 polyfunctionality or the Th17/Treg ratio was associated with a lower viral burden during the period of cART (Figure 1a,b,d). In contrast, expansion of T regulatory cells in the colon during acute infection was associated with greater viral burden during (Figure 1c). These data indicate that less gut immune T cell dysregulation during acute infection is associated with lower viral burden during cART.
    Figure 1. Less dysregulation of mucosal CD4 T-cells is associated with greater viral control during cART. Correlations between log10-fold change in colonic (a) Th17 and (b) Treg cell frequencies, (c) the Th17/ratio, and (d) Th17 polyfunctionality (Th17 Poly.) during acute infection (weeks 0–6) versus AUC plasma viremia during cART (weeks 9–28). Spearman’s rank correlation is shown, with * p-values ≤0.05 considered significant.

    3. Discussion

    The success of NHP AIDS models has led to increased demand in NHPs in recent years [18], but appropriate selection of a pre-clinical SIV/SHIV NHP model is critical when evaluating HIV interventions. In these studies, we report less variability in viral control during cART in SHIV-1157ipd3N4 versus SIVΔB670-infected RMs. Specifically, 9/19 SIV-infected animals did not exhibit sustained virologic control during cART compared to SHIV-infected animals which maintained low/undetectable levels of viral replication within a few weeks of starting cART. During treated human HIV infection viral suppression is regularly achieved within 12–24 weeks [19] and is highly consistent with the responses in SHIV-infected animals reported here. Historically, control of SIVΔB670 replication by antiviral drugs has been highly variable, with some animals unable to control viral replication despite 9 months of treatment [9]. While we cannot rule out that longer treatment could result in undetectable levels of plasma viremia, our results indicate that greater restoration of mucosal T-cell functions occurs in animals that exhibit more immediate control of viremia after initiating cART. These studies were limited to evaluation of viral burden in the blood. Studies in NHP have shown a relationship between plasma and tissue levels of virus replication [20][21] and decreased penetrance of antiretrovirals to mucosal sites [22], so it is likely that animals with high plasma viremia also had greater viral burden at mucosal sites. Future studies are needed to evaluate the viral burden in mucosal compartments to determine the relationship between local viral replication and mucosal CD4 T-cells more conclusively. Antiretroviral drugs designed to inhibit HIV replication can be less efficient in suppressing SIV viral replication and can often take months to achieve durable viral suppression and our findings are consistent with previous reports [23][24]. Although the classes of cART regimens were similar, studies in humans have revealed higher interpatient pharmacokinetic variability with RAL, that was used in ourSIV infected RMs, and less variability with DTG, that was given to our SHIV infected RMs [25]. This may explain the increased variability in viral control we see in the SIV-infected RMs. In addition, all three drugs given to the SHIV-infected animals were injectable, whereas one drug (RAL) was delivered orally in the SIV-infected animals; this may have influenced relative cART “adherence” and effectiveness of this regimen in the SIV-infected animals. Alternatively, if the SIV-infected animals were given the same ART regimen as the SHIV-infected animals (e.g., TDF, FTC, DTG) greater viral suppression may have occurred. This specific drug regimen was given to 3 SIVmac239X infected rhesus macaques 2 weeks after infection, yet stable viral suppression was also not achieved until 12–20 weeks following cART [26]. These data suggest that even if the SIVΔB670-infected RMs had been given a cART regimen of TDF, FTC, DTG, viral suppression may have been incomplete or taken longer than during SHIV infection, thus allowing a greater period to disrupt gut immunostasis.
    Sustained virologic control during cART, primarily in SHIV-1157ipd3N4-infected RMs, corresponded with less dysregulation of the Th17/Treg ratio during acute infection. These results highlight differences in viral suppression during cART responsiveness in NHP models during cART with 100% of SHIV-1157ipd3N4 and only 53% of SIVΔB670-infected RMs reaching virologic control on cART. Furthermore, better virologic control in response to cART corresponded to less mucosal immune dysfunction, including higher Th17/Treg ratios and lower gut immune activation in SHIV than in SIV-infected animals. These results demonstrate that the SIV and SHIV NHP AIDS models recapitulate aspects of mucosal immune dysfunction found during HIV infection, with signs of increased mucosal pathogenesis in SIVΔB670-infected RMs. Additionally, we found that increased pathogenesis during acute infection leads to greater disruption of mucosal CD4 T-cells and corresponds to poorer virologic control during cART. However, several differences in the experimental design, including virus strain, inoculation dose, time of cART initiation and drug regimen, etc. can influence the mucosal environment, and therefore, differences between the SHIV and SIV models that we report here. Thus, the level of viral pathogenesis not only in the periphery, but also at mucosal sites, needs to be considered when determining whether to use SHIV or SIV NHP models in HIV vaccine studies.
    Early cART treatment during HIV infection has been shown to preserve CD4 and Th17 cells in the gut, but has been less successful in reversing persistent gut inflammation, reducing chronic immune activation, or eliminating viral reservoirs [27][28]. During treated human HIV infection, early cART initiation was found to restore Th17 cell numbers, but not Th17 polyfunctionality and demonstrates how early stages of the infection can have detrimental long-term influences on mucosal T-cell compartments [29]. Consistent with these findings, we found that mucosal CD4 and Th17 restoration during cART was similar in both infection models, restoration of Th17 polyfunctionality was greater in SHIV infected RMs. Therefore, the SHIV model reported here may better recapitulate aspects of gut mucosal dysfunction observed in cART-treated people living with HIV. This is likely due to the lower viral replication and more efficient suppression of viral replication on cART in the SHIV model. Although cART improves some aspects of HIV infection and disease progression, the findings reported here, including chronic immune activation and dysregulation of Th17 and Treg cells, suggest that strategies to improve gut mucosal homeostasis may increase the effectiveness of immunotherapies aimed to treat or cure HIV infection. Furthermore, our results provide strong evidence that both the SIV and SHIV macaque models of AIDS recapitulate declines in mucosal T-cell function and immune activation, but that the SHIV infection model may more closely mimic this relationship in treated people living with HIV.
    Structural barriers and gaps in the HIV care continuum have led to many people living with untreated HIV. As of 2020, 27% of people with a known HIV status did not have access to cART and of those receiving treatment 44% were not virally suppressed [30]. Failure to achieve long-term HIV viral suppression during cART, due to noncompliance, drug resistance, or other factors, is associated with increased risk of AIDS- and non-AIDS associated co-morbidities [31] and could ultimately influence the efficacy of HIV intervention strategies. Spontaneous viral remission occurs in untreated individuals [32] or post-treatment controllers after analytic treatment interruption [33] and can lead to overestimations in the effectiveness of therapies. Thus, the SIV model, which exhibited greater immune dysregulation consistent with suboptimal cART regimens, may better recapitulate individuals with less accessibility or poorer adherence to cART. Variability of virologic control during cART in pre-clinical NHP AIDS models may impact the relative evaluation of candidate therapeutic interventions for HIV cure in humans and selection of an appropriate NHP model that represents the target population for a given therapeutic is critical. The SHIV macaque model may be better for identifying initial vaccine candidates, but it may be necessary, when possible, to switch to a SIV model, that has greater variability in cART viral control and gut immune dysfunction, to model aspects of real-world scenarios of cART nonadherence or unsuppressed HIV replication.

    The entry is from 10.3390/v13081609


    1. Evans, D.T.; Silvestri, G. Non-Human Primate Models in AIDS Research. Curr. Opin. HIV AIDS 2013, 8, 255–261.
    2. Hatziioannou, T.; Evans, D.T. Animal Models for HIV/AIDS Research. Nat. Rev. Microbiol. 2012, 10, 852–867.
    3. Bar, K.J.; Coronado, E.; Hensley-McBain, T.; O’Connor, M.A.; Osborn, J.M.; Miller, C.; Gott, T.M.; Wangari, S.; Iwayama, N.; Ahrens, C.Y.; et al. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. J. Virol. 2019, 93.
    4. Favre, D.; Lederer, S.; Kanwar, B.; Ma, Z.-M.; Proll, S.; Kasakow, Z.; Mold, J.; Swainson, L.; Barbour, J.D.; Baskin, C.R.; et al. Critical Loss of the Balance between Th17 and T Regulatory Cell Populations in Pathogenic SIV Infection. PLoS Pathog. 2009, 5, e1000295.
    5. Khowawisetsut, L.; Pattanapanyasat, K.; Onlamoon, N.; Mayne, A.E.; Little, D.M.; Villinger, F.; Ansari, A.A. Relationships between IL-17(+) Subsets, Tregs and PDCs That Distinguish among SIV Infected Elite Controllers, Low, Medium and High Viral Load Rhesus Macaques. PLoS ONE 2013, 8, e61264.
    6. Amedee, A.M.; Lacour, N.; Gierman, J.L.; Martin, L.N.; Clements, J.E.; Bohm, R.; Harrison, R.M.; Murphey-Corb, M. Genotypic Selection of Simian Immunodeficiency Virus in Macaque Infants Infected Transplacentally. J. Virol. 1995, 69, 7982–7990.
    7. Hong, F.F.; Mellors, J.W. Changes in HIV Reservoirs during Long-Term Antiretroviral Therapy. Curr. Opin. HIV AIDS 2015, 10, 43–48.
    8. Hunt, P.W. Th17, Gut, and HIV: Therapeutic Implications. Curr. Opin. HIV AIDS 2010, 5, 189–193.
    9. Fuller, D.H.; Rajakumar, P.; Che, J.W.; Narendran, A.; Nyaundi, J.; Michael, H.; Yager, E.J.; Stagnar, C.; Wahlberg, B.; Taber, R.; et al. Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques. PLoS ONE 2012, 7, e33715.
    10. Tunggal, H.C.; Munson, P.V.; O’Connor, M.A.; Hajari, N.; Dross, S.E.; Bratt, D.; Fuller, J.T.; Bagley, K.; Fuller, D.H. Effects of Therapeutic Vaccination on the Control of SIV in Rhesus Macaques with Variable Responsiveness to Antiretroviral Drugs. PLoS ONE 2021, 16, e0253265.
    11. O’Connor, M.A.; Munson, P.V.; Tunggal, H.; Hajari, N.; Lewis, T.B.; Bratt, D.; Moats, C.; Smedley, J.; Bagley, K.; Mullins, J.I.; et al. Mucosal T Helper 17 and T Regulatory Cell Homeostasis Correlates with Acute Simian Immunodeficiency Virus Viremia and Responsiveness to Antiretroviral Therapy in Macaques. AIDS Res. Hum. Retrovir. 2019, 35, 295–305.
    12. Falivene, J.; Ghiglione, Y.; Laufer, N.; Eugenia Socías, M.; Pía Holgado, M.; Julia Ruiz, M.; Maeto, C.; Inés Figueroa, M.; Giavedoni, L.D.; Cahn, P.; et al. Th17 and Th17/Treg Ratio at Early HIV Infection Associate with Protective HIV-Specific CD8(+) T-Cell Responses and Disease Progression. Sci. Rep. 2015, 5, 11511.
    13. Ponte, R.; Mehraj, V.; Ghali, P.; Couëdel-Courteille, A.; Cheynier, R.; Routy, J.-P. Reversing Gut Damage in HIV Infection: Using Non-Human Primate Models to Instruct Clinical Research. EBioMedicine 2016, 4, 40–49.
    14. Baskin, G.B.; Murphey-Corb, M.; Watson, E.A.; Martin, L.N. Necropsy Findings in Rhesus Monkeys Experimentally Infected with Cultured Simian Immunodeficiency Virus (SIV)/Delta. Vet. Pathol. 1988, 25, 456–467.
    15. Murphey-Corb, M.; Martin, L.N.; Rangan, S.R.; Baskin, G.B.; Gormus, B.J.; Wolf, R.H.; Andes, W.A.; West, M.; Montelaro, R.C. Isolation of an HTLV-III-Related Retrovirus from Macaques with Simian AIDS and Its Possible Origin in Asymptomatic Mangabeys. Nat. Cell Biol. 1986, 321, 435–437.
    16. Song, R.J.; Chenine, A.-L.; Rasmussen, R.A.; Ruprecht, C.R.; Mirshahidi, S.; Grisson, R.D.; Xu, W.; Whitney, J.B.; Goins, L.M.; Ong, H.; et al. Molecularly Cloned SHIV-1157ipd3N4: A Highly Replication- Competent, Mucosally Transmissible R5 Simian-Human Immunodeficiency Virus Encoding HIV Clade C Env. J. Virol. 2006, 80, 8729–8738.
    17. Humbert, M.; Rasmussen, R.A.; Song, R.; Ong, H.; Sharma, P.; Chenine, A.L.; Kramer, V.G.; Siddappa, N.B.; Xu, W.; Else, J.G.; et al. SHIV-1157i and Passaged Progeny Viruses Encoding R5 HIV-1 Clade C Env Cause AIDS in Rhesus Monkeys. Retrovirology 2008, 5, 94.
    18. Grimm, D.U.S. Labs Using a Record Number of Monkeys. Science 2018, 362, 630.
    19. Hoenigl, M.; Chaillon, A.; Moore, D.J.; Morris, S.R.; Mehta, S.R.; Gianella, S.; Amico, K.R.; Little, S.J. Rapid HIV Viral Load Suppression in Those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. Sci. Rep. 2016, 6, 32947.
    20. Pahar, B.; Kuebler, D.; Rasmussen, T.; Wang, X.; Srivastav, S.K.; Das, A.; Veazey, R.S. Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques. Front. Microbiol. 2019, 10, 2933.
    21. Mannioui, A.; Bourry, O.; Sellier, P.; Delache, B.; Brochard, P.; Andrieu, T.; Vaslin, B.; Karlsson, I.; Roques, P.; Le Grand, R. Dynamics of Viral Replication in Blood and Lymphoid Tissues during SIVmac251 Infection of Macaques. Retrovirology 2009, 6, 106.
    22. Wong, J.K.; Yukl, S.A. Tissue Reservoirs of HIV. Curr. Opin. HIV AIDS 2016, 11, 362–370.
    23. Del Prete, G.Q.; Lifson, J.D. Considerations in the Development of Nonhuman Primate Models of Combination Antiretroviral Therapy for Studies of AIDS Virus Suppression, Residual Virus, and Curative Strategies. Curr. Opin. HIV AIDS 2013, 8, 262–272.
    24. Del Prete, G.Q.; Shoemaker, R.; Oswald, K.; Lara, A.; Trubey, C.M.; Fast, R.; Schneider, D.K.; Kiser, R.; Coalter, V.; Wiles, A.; et al. Effect of Suberoylanilide Hydroxamic Acid (SAHA) Administration on the Residual Virus Pool in a Model of Combination Antiretroviral Therapy-Mediated Suppression in SIVmac239-Infected Indian Rhesus Macaques. Antimicrob. Agents Chemother 2014, 58, 6790–6806.
    25. Podany, A.T.; Scarsi, K.K.; Fletcher, C.V. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. Clin. Pharmacokinet. 2017, 56, 25–40.
    26. Del Prete, G.Q.; Smedley, J.; Macallister, R.; Jones, G.S.; Li, B.; Hattersley, J.; Zheng, J.; Piatak, M.; Keele, B.F.; Hesselgesser, J.; et al. Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques. AIDS Res. Hum. Retrovir. 2016, 32, 163–168.
    27. Crakes, K.R.; Jiang, G. Gut Microbiome Alterations During HIV/SIV Infection: Implications for HIV Cure. Front. Microbiol. 2019, 10, 1104.
    28. Younas, M.; Psomas, C.; Reynes, J.; Corbeau, P. Immune Activation in the Course of HIV-1 Infection: Causes, Phenotypes and Persistence under Therapy. HIV Med. 2016, 17, 89–105.
    29. Schuetz, A.; Deleage, C.; Sereti, I.; Rerknimitr, R.; Phanuphak, N.; Phuang-Ngern, Y.; Estes, J.D.; Sandler, N.G.; Sukhumvittaya, S.; Marovich, M.; et al. Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. PLoS Pathog. 2014, 10, e1004543.
    30. November 25, C.S.H. govDate Last Updated; 2020 Global Statistics. Available online: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (accessed on 12 August 2021).
    31. Park, L.S.; Tate, J.P.; Sigel, K.; Brown, S.T.; Crothers, K.; Gibert, C.; Goetz, M.B.; Rimland, D.; Rodriguez-Barradas, M.C.; Bedimo, R.J.; et al. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Ann. Intern. Med. 2018, 169, 87–96.
    32. Martin, G.E.; Gossez, M.; Williams, J.P.; Stöhr, W.; Meyerowitz, J.; Leitman, E.M.; Goulder, P.; Porter, K.; Fidler, S.; Frater, J.; et al. Post-Treatment Control or Treated Controllers? Viral Remission in Treated and Untreated Primary HIV Infection. AIDS 2017, 31, 477–484.
    33. Namazi, G.; Fajnzylber, J.M.; Aga, E.; Bosch, R.J.; Acosta, E.P.; Sharaf, R.; Hartogensis, W.; Jacobson, J.M.; Connick, E.; Volberding, P.; et al. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J. Infect. Dis. 2018, 218, 1954–1963.